Drug repositioning or repurposing is playing a significant role in advancing new therapeutic innovations, complementing traditional drug discovery approaches to enhance therapeutic efficacy. The repurposing or repositioning of drugs involves considerations related to the drugs which are not in use or have shown more than one or other therapeutic effects, marking the commencement of a new era for pharmaceuticals and exploring new market opportunities and value. It has given a reoccurrence or a new opportunity to all the drugs which are currently undergoing clinical trials or those that have been withdrawn from the market. This approach aims to overcome the limitations of traditional methods, resources, and time. Despite economic and regulatory challenges, drug repositioning has played a crucial role in various pathological fields, public health benefits, and commercial value. Notable examples of drugs that have undergone repositioning include sildenafil, dimethylfumarate, acetylsalicylic acid, and thalidomide. The history of repositioned drugs